Vesna Bjelic‐Radisic
A5022097827- Breast Cancer Treatment Studies
- Pelvic floor disorders treatments
- Breast Implant and Reconstruction
- Cancer survivorship and care
- Anorectal Disease Treatments and Outcomes
- Breast Lesions and Carcinomas
- Cancer Treatment and Pharmacology
- Reconstructive Surgery and Microvascular Techniques
- Cancer Risks and Factors
- Advanced Breast Cancer Therapies
- Cancer Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Bone health and treatments
- Estrogen and related hormone effects
- Radiopharmaceutical Chemistry and Applications
- Ovarian cancer diagnosis and treatment
- Urinary Tract Infections Management
- HER2/EGFR in Cancer Research
- Medical Imaging Techniques and Applications
- Global Cancer Incidence and Screening
- Urinary Bladder and Prostate Research
- BRCA gene mutations in cancer
- Cervical Cancer and HPV Research
- Pelvic and Acetabular Injuries
- Cancer Genomics and Diagnostics
Helios Universitätsklinikum Wuppertal
2018-2025
Medical University of Graz
2016-2025
Witten/Herdecke University
2018-2025
Austrian Breast & Colorectal Cancer Study Group
2009-2025
University of Wuppertal
2020-2021
AGO Austria
2019-2021
International Breast Cancer Study Group
2021
Universitätsklinik für Frauenheilkunde und Geburtshilfe
2008-2020
Medical University of Vienna
2009-2019
Vienna General Hospital
2009-2019
Ovarian suppression plus tamoxifen is a standard adjuvant treatment in premenopausal women with endocrine-responsive breast cancer. Aromatase inhibitors are superior to postmenopausal patients, and preclinical data suggest that zoledronic acid has antitumor properties.
Background: Conflicting evidence exists regarding the value of surgical resection primary in stage IV breast cancer patients. Objective: The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median survival comparing surgery followed by systemic therapy to de novo cancer. Methods: Between 2011 and 2015, 90 previously untreated patients were randomly assigned tumor (Arm A) or B) Austria. Overall (OS) was defined as study endpoint. Results: stopped early due poor recruitment....
Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking. Download a PDF Research Summary. We conducted single-group trial in which we evaluated temporary interruption adjuvant young previous cancer. Eligible were 42 years age or younger; had stage I, II, III disease; received for 18 30 months; and desired pregnancy. The primary end point was number events (defined...
For postmenopausal women with hormone-receptor-positive breast cancer, the most effective duration for adjuvant therapy an aromatase inhibitor remains unclear.In this prospective, phase 3 trial, we randomly assigned cancer who had received 5 years of endocrine to receive anastrozole additional 2 (2-year group, receiving a total 7 years) or (5-year 10 years). The primary end point was disease-free survival. analysis included all patients were still participating in trial and no recurrence...
Aromatase inhibitors are effective as endocrine treatment for patients with hormone receptor-positive breast cancer. According to the hypothesis that overweight have higher levels of aromatase enzyme availability, we investigated influence body mass index (BMI) on efficacy adjuvant therapy in premenopausal a retrospective analysis Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 trial.ABCSG-12 examined ovarian suppression using goserelin (3.6 mg subcutaneously every 28 days)...
Background: Umbilical cord blood (UCB) is an easily accessible alternative source for multipotent mesenchymal stromal cells (MSCs) and generally believed to provide MSCs with a higher proliferative potential compared adult bone marrow. Limitations in cell number strict dependence of expansion procedures from selected lots fetal bovine serum have hampered the progress clinical applications UCB-derived MSCs. Methods: We analyzed isolation human UCB marrow under optimized ex vivo culture...
The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer.
Nanoparticles, which are exposed to biological fluids rapidly interacting with proteins and other biomolecules forming a corona. In addition dimension, charge material the distinct protein corona influences interplay of nanoparticles tissue barriers. this study we were focused on impact in situ formed human plasma transfer 80 nm polystyrene (PS-particles) across placenta. To materno-to fetal PS used ex vivo placental perfusion approach, represents an intact physiological barrier. analyze...
Demand for nipple- and skin- sparing mastectomy (NSM/SSM) with immediate breast reconstruction (BR) has increased at the same time as indications post-mastectomy radiation therapy (PMRT) have broadened. The aim of Oncoplastic Breast Consortium initiative was to address relevant questions arising this clinically challenging scenario.A large global panel oncologic, oncoplastic reconstructive surgeons, patient advocates oncologists developed recommendations clinical practice in an iterative...
We investigated time to pregnancy, efficacy and safety of fertility preservation, assisted reproductive technologies (ARTs) in women with early hormone receptor-positive breast cancer (BC) desiring future pregnancy.
Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology Obstetrics (DGGG) Cancer (DKG) was to optimize screening, diagnosis, therapy follow-up care breast cancer. Method process updating S3 in 2012 based on adaptation identified source guidelines. They were combined with reviews evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions results a systematic search literature databases followed selection evaluation...